Study the Molar Ratio of the Reaction between Thalassemia s Drug (Deferoxamine) with Iron Over loud
نویسنده
چکیده
Iron-Deferoxamine complex have been synthesized in vitro by the reaction of deferoxamine (which are use as therapeutic agent for removing iron overload from the bodies of thalassemia patients) with Fe(II) salt in aqueous medium. The geometry of the prepared complex as well as the mode of bonding were determined through FTIR, UV-Vis, mass spectral studies, metal content, and molar conductance. These studies revealed octahedral geometry for the complex with the general formula [Fe II (DEF)]Cl2. Complex formation via molar ratio method and variation continuous method in aqueous solution have been also investigated and results were consistent to those found in the solid complexes with a ratio of (M:L) as (1 : 1). Conditional formation constant could also be calculated for [Fe II (DEF)]Cl2 as 2.0 × 10 3 . The effect of time on the formation of Iron – Deferoxamine complex has been also studied. This study showed that each 1×10 -3 M of deferoxamine needs 2.5 – 3 hrs to remove 1×10 -3 M of Iron (II) by formation coordination complex.
منابع مشابه
The Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major
Background: Deferoxamine mesylate is still the conventional and well-known iron chelator for patients with thalassemia major. However, due to some marketing issues the well-known original brand, Desferal®, produced by Novartis Pharmaceuticals Company is not as available as before. The generic brands of Deferoxamine have been introduced in many parts of the world including Iran; however, they ar...
متن کاملSequential Deferoxamine - Deferasirox in Treatment of Major Thalassemia with Iron Overload
Abstract Background Iron overload is a major problem in patients with major thalassemia. An effective and safe iron chelator protocol with high compliance rate plays an important role in treatment of these patients. This study was done to assess the efficacy and safety of the sequential deferoxamine and deferasirox protocol in major thalassemia patients in Khuzestan province, Iran. Material ...
متن کاملEffect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial
Background: Patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. The aim of this study was to compare effect of combined versus monotherapy with Deferoxamine (DFO) and Deferiprone (DFP) in iron overloaded beta thalassemia (BT) major patients Materials and Methods We studied 36 BT major patients (mea...
متن کاملComparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
Background: Cardiac complications due to iron overload are the most common cause of death in patients with thalassemia major. The aim of this study was to compare iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on cardiac and liver iron load measured by T2* MRI. Methods: In this study, 108 patients with thalassemia major aged over 10 years...
متن کاملComparison of Magnetic Resonance Imaging T2 Results in Beta-Thalassemia Patients Treated by Deferasirox or Combination of Deferoxamine and Deferiprone
Background: Iron extra load is an anticipated and lethal consequence of chronic blood transfusion in major beta-thalassemia patients; therefore it is necessary to use an efficient iron chelator drug to stimulate the evacuation of the surplus iron from the body. This trial was performed to compare myocardial and hepatic magnetic resonance imaging T2 (MRI T2*) results of beta-thalassemia patients...
متن کامل